Searchable abstracts of presentations at key conferences in endocrinology

ea0056p765 | Neuroendocrinology | ECE2018

Rathke’s cleft cyst mimiking pituitary apoplexy: a case report

Barka Ines , Bensmaine Faiza , Bah Moctar , Bouche Clara , Gautier Jean Francois

Introduction: The most common sellar lesions are mainly due to pituitary adenomas, craniopharyngiomas and benign cysts. Rathke’s cleft cyst (RCC) is a developmental sellar or suprasellar cystic lesion, which rarely becomes symptomatic. Here, we present an interesting case of intra sellar RCC, with a presenting feature of acute pituitary apoplexy.Case report: A 39 year old healthy women was referred to the emergency room for sudden headache and fatig...

ea0056p780 | Pituitary - Basic | ECE2018

Pituitary cell activation and recruitment in hipothyroidism

Oroz Fernando , Garcia-Lavandeira Montserrat , Perez-Romero Sihara , Garcia-Rendueles Angela , Alvarez Clara V

Pituitary stem cells have been characterized in the postnatal pituitary. We now know they are organized in a niche and co-express specific markers such as Sox2, Sox9 or Gfra2. Although many studies by our group and others have been dedicated to its characterization in situ it is under discussion their role in the maintenance and turnover of the pituitary in physiological conditions or physiological pituitary challenges. It’s not known if the stem cells are requir...

ea0056p895 | Clinical case reports - Thyroid/Others | ECE2018

Hypergonadotropic hypogonadism secondary to vanishing testes syndrome newly diagnosed in a 42-year-old male patient

Sousa Santos Francisco , Capitao Ricardo , Ferrinho Catia , Cunha Clara , Limbert Clotilde , Vasconcelos Carlos

Introduction: Cryptorchidism is the most common abnormality of male sexual development. Approximately 5% of cases of cryptorchidism are associated with vanishing testes syndrome. This rare condition occurs when an initially normal testicle that existed in fetal life subsequently atrophies. Affected patients usually have normal male external genitalia and hypergonadotropic hypogonadism. This disease is usually diagnosed in early childhood allowing for normal sexual development ...

ea0056p942 | Female Reproduction | ECE2018

Recombinant FSH and biosimilars result in different intracellular signaling

Riccetti Laura , Sperduti Samantha , Lazzaretti Clara , Tagliavini Simonetta , Simoni Manuela , Casarini Livio

Introduction: Follicle-stimulating hormone (FSH) biosimilars, differing for source cell and glycosylation pattern, are commercially available for therapy of hypogonadism and assisted reproduction techniques (ART). Although these molecules are commonly used in clinical practice, comparison of their action in vitro was poorly investigated.Aim: The aim of the study is to compare recombinant FSH- and biosimilars-induced cell response in vitro</e...

ea0056p1044 | Thyroid (non-cancer) | ECE2018

Usefulness of ultrasound evaluation of thyroid nodules in predicting malignancy

Atienza Elena , Trifu Daniela Stefania , Tasende Clara , Escribano Pablo , Saavedra Pilar , Rubio Jose Antonio , Blanco Concepcion

Introduction: Ultrasound (US) thyroid examination is the most common method to assess thyroid nodules risk of malignancy and select nodules for fine-needle aspiration biopsy (FNAB). Thyroid US evaluation performed by endocrinologists has recently increased in Spain.Objectives: To evaluate the predictive value of US features of malignancy in differentiating benign and malignant thyroid lesions in a Thyroid Nodule Clinic.Patients and...

ea0056p1192 | Thyroid cancer | ECE2018

Tyrosine kinase inhibitors in iodine-refractory thyroid cancer. Clinical experience

Marijuan Clara , Pla Begona , Aguirre Nerea , Fernandez Elena , Hernando Inigo , Jimenez Sara , Marazuela Monica , Lahera Marcos

Introduction: Tyrosine kinase inhibitors (TKIs) are used for treatment of iodine-refractory differentiated thyroid cancer (DTC) in patients with progressive advanced disease.Sorafenib and lenvatinib are the TKIs currently approved for this indication.Objective: To describe the clinical experience in patients with iodine-refractory DTC treated with TKIs in our Institution.Materials and methods: Restrospective cohort study of patient...

ea0073aep17 | Adrenal and Cardiovascular Endocrinology | ECE2021

Cost-effectiveness of empagliflozin plus metformin vs metformin alone as first-line therapy in patients with type 2 diabetes mellitus: An australian perspective

Abushanab Dina , Liew Danny , marquina Clara , Al-Badriyeh Daoud , Ademi Zanfina

BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors are potentially an attractive option for initial combination therapy with metformin for type 2 diabetes mellitus (T2DM), which may help patients to achieve adequate glycaemic control and reduce cardiovascular disease (CVD). Empagliflozin has been shown to be superior compared to other SGLT2 inhibitors in reducing all-cause and cardiovascular mortality in patients with T2DM.<p class="abstext"...

ea0073aep527 | Pituitary and Neuroendocrinology | ECE2021

Copeptin predicts clinical outcome in schizophrenia spectrum disorder

Sailer Clara , Jennifer Küster , Borgwardt Stefan , Christ-Crain Mirjam

BackgroundVasopressin, the main hormone regulating sodium-water balance, is involved in higher brain functions, e.g., cognition, emotion regulation and social functioning. In patients with an acute psychotic episode, increased vasopressin levels have been described and impaired higher brain functions are associated. Copeptin, the stable surrogate marker of vasopressin, has been shown to predict outcome in somatic diseases, i.e., stroke, myocardial infarc...

ea0099oc8.2 | Oral Communications 8: Thyroid | ECE2024

Antigen-specific peptide immunotherapy attenuates the pathogenic response in a murine model of Graves’ disease

Cho Yi-Li , Wenhart Clara , Gobel Silvia , Reimann Andreas , Li Zhongmin , Munch Gotz

Background: Graves’ disease (GD) is an autoimmune disease caused by autoantibody targeting the thyrotropin receptor (TSHR) in the thyroid gland, resulting in hyperthyroidism with an annual incidence of 15 to 80/100,000 people worldwide. Current mainstream treatments for GD include aggressive treatment with radioiodine and thyroidectomy or unspecific immune-modulating therapy with glucocorticoids, antithyroid medications or anti-CD20 antibodies like Rituximab. Therefore, o...

ea0099p306 | Endocrine-Related Cancer | ECE2024

Long-acting starch (Glycosade(R)): An effective treatment for insulinoma-induced hypoglycemia – A case report

Arias Karen Andrea Castillo , Duminy Diego , Mora Mireia , Vinals Clara , Hanzu Felicia A , OROIS AIDA , Pane Adriana

Introduction: Insulinoma is a rare, generally benign neuroendocrine tumor, primarily manifesting as hypoglycemia in non-diabetic patients. Although surgery is the gold standard treatment for insulinoma, managing hypoglycemia becomes challenging in cases where surgery is not feasible. This challenge arises due to significant side effects that often limit the use of most drugs and therapeutic alternatives.Case report: A 90-year-old non-diabetic man was adm...